Goldman Sachs Upgrades Mylan (MYL) to Buy, Sees Earnings Revised Higher
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded Mylan (NASDAQ: MYL) from Neutral to Buy with a price target of $27 (up from $23).
The firm said they have increased confidence in the company's earnings visibility, and they see Street estimates revised higher which will drive the stock. Goldman notes that investors have skeptical of the company's 2013 EPS target, given concerns about exposure to EU and Asia-Pacific generics which have see soft pricing.
While the firm lowered estimates further to account for these headwinds, they see the strategy to re-value its EpiPen brand franchise to more than offset and provide significant growth.
The firm sees FY11 EPS of $2.01, FY12 of $2.53 and FY13 of $2.70.
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $22.96 yesterday.
The firm said they have increased confidence in the company's earnings visibility, and they see Street estimates revised higher which will drive the stock. Goldman notes that investors have skeptical of the company's 2013 EPS target, given concerns about exposure to EU and Asia-Pacific generics which have see soft pricing.
While the firm lowered estimates further to account for these headwinds, they see the strategy to re-value its EpiPen brand franchise to more than offset and provide significant growth.
The firm sees FY11 EPS of $2.01, FY12 of $2.53 and FY13 of $2.70.
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $22.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Vivos Therapeutics posts 35% revenue gain but widens net loss
- Diana Shipping drops bid for Genco after price demands spike to $36.91
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
